Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Clinical Trials Arena on MSN

Immuneering progresses MAPK inhibitor in lung and pancreatic cancer

The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.
CU Boulder News & Events

Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles (Science Signaling 2023)

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Nature

Yeast Filamentous Growth and MAPK Signaling Pathways

Yeast filamentous growth is a highly regulated cellular differentiation response, enabling cells to assume an elongated morphology when confronted with environmental stress or nutrient limitation.